Therapeutic nanomedicine for brain cancer

Therapeutic Delivery

Volumn 4, Issue 6, 2013, Pages 687-704

  Tzeng, Stephany Y ^a   Green, Jordan J ^a  

^a Smith Building 5017   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPEPTIN; APOLIPOPROTEIN A1; APOLIPOPROTEIN E; BETA AMINO ACID; BETA INTERFERON; CONTRAST MEDIUM; DENDRIMER; DOXORUBICIN; FLUOROURACIL; FOLIC ACID; GANCICLOVIR; GLUTATHIONE; INSULIN RECEPTOR; INTERLEUKIN 13; LIPOSOME; LOW DENSITY LIPOPROTEIN RECEPTOR; MACROGOL; NANOCAPSULE; NANOPARTICLE; POLOXAMER; POLYAMIDOAMINE; POLYESTER; POLYGLACTIN; POLYGLYCOLIC ACID; POLYLACTIC ACID; POLYMER; SERUM ALBUMIN; TRANSFERRIN; TRANSFERRIN RECEPTOR; UNINDEXED DRUG;

ASTROCYTE; BLOOD BRAIN BARRIER; BRAIN CANCER; BRAIN TISSUE; CANCER CELL; CANCER STEM CELL; CELL HOMING; CHEMICAL MODIFICATION; DIAGNOSTIC IMAGING; DIFFUSION; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG HALF LIFE; DRUG PENETRATION; DRUG RETENTION; DRUG TARGETING; ENDOTHELIUM CELL; GLIOMA CELL; HUMAN; MEMBRANE PERMEABILITY; MESENCHYMAL STEM CELL; MOLECULAR IMAGING; NANOMEDICINE; NEURAL STEM CELL; NEUROIMAGING; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; NUCLEAR MAGNETIC RESONANCE IMAGING; PARTICLE SIZE; PHAGOCYTE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; SURFACE PROPERTY; THERMODYNAMICS; TUMOR MICROENVIRONMENT; VIRAL GENE DELIVERY SYSTEM; VIRUS PARTICLE;

EID: 84878740395     PISSN: 20415990     EISSN: 20416008     Source Type: Journal    
DOI: 10.4155/tde.13.38     Document Type: Review

References (139)

1. Chithrani BD, Ghazani AA, Chan WCW. Determining the size and shape dependence of gold nanoparticle uptake into mammalian cells. Nano Lett. 6(4), 662-668 (2006).
2. Behin A, Hoang-Xuan K, Carpentier AF, Delattre JY. Primary brain tumours in adults. Lancet 361(9354), 323-331 (2003).
3. Palanichamy K, Erkkinen M, Chakravarti A. Predictive and prognostic markers in human glioblastomas. Curr. Treat. Options Oncol. 7(6), 490-504 (2006).
4. Brandsma D, van den Bent MJ. Molecular targeted therapies and chemotherapy in malignant gliomas. Curr. Opin. Oncol. 19(6), 598-605 (2007).
5. Bala I, Hariharan S, Kumar MNVR. PLGA nanoparticles in drug delivery: the state of the art. Crit. Rev. Ther. Drug Carrier Syst. 21(5), 387-422 (2004).
6. Mitra S, Gaur U, Ghosh PC, Maitra AN. Tumour targeted delivery of encapsulated dextran-doxorubicin conjugate using chitosan nanoparticles as carrier. J. Control. Release 74(1-3), 317-323 (2001).
7. Park JH, Saravanakumar G, Kim K, Kwon IC. Targeted delivery of low molecular drugs using chitosan and its derivatives. Adv. Drug Delivery. Rev. 62(1), 28-41 (2010).
8. Shenoy D, Little S, Langer R, Amiji M. Poly(ethylene oxide)-modified poly(beta-amino ester) nanoparticles as a pH-sensitive system for tumor-targeted delivery of hydrophobic drugs: part 2. In vivo distribution and tumor localization studies. Pharm. Res. 22(12), 2107-2114 (2005).
9. Tzeng SY, Guerrero-Cazares H, Martinez EE, Sunshine JC, Quinones-Hinojosa A, Green JJ. Non-viral gene delivery nanoparticles based on poly(beta-amino esters) for treatment of glioblastoma. Biomaterials 32(23), 5402-5410 (2011).
10. He H, Li Y, Jia XR et al. PEGylated Poly(amidoamine) dendrimer-based dual-targeting carrier for treating brain tumors. Biomaterials 32(2), 478-487 (2011).
11. Malam Y, Loizidou M, Seifalian AM. Liposomes and nanoparticles: nanosized vehicles for drug delivery in cancer. Trends Pharmacol. Sci. 30(11), 592-599 (2009).
12. Hofheinz RD, Gnad-Vogt SU, Beyer U, Hochhaus A. Liposomal encapsulated anti-cancer drugs. Anti-Cancer Drugs 16(7), 691-707 (2005).
13. Weinstein JS, Varallyay CG, Dosa E et al. Superparamagnetic iron oxide nanoparticles: diagnostic magnetic resonance imaging and potential therapeutic applications in neurooncology and central nervous system inflammatory pathologies, a review. J. Cereb. Blood Flow Metab. 30(1), 15-35 (2010).
14. Kawano T, Yamagata M, Takahashi H et al. Stabilizing of plasmid DNA in vivo by PEG-modified cationic gold nanoparticles and the gene expression assisted with electrical pulses. J. Control. Release 111(3), 382-389 (2006).
15. Lee J-S, Green JJ, Love KT, Sunshine J, Langer R, Anderson DG. Gold, poly(B-amino ester) nanoparticles for small interfering RNA delivery. Nano Lett. 9(6), 2402-2406 (2009).
16. Lu J, Liong M, Zink JI, Tamanoi F. Mesoporous silica nanoparticles as a delivery system for hydrophobic anticancer drugs. Small 3(8), 1341-1346 (2007).
17. Tanaka T, Mangala LS, Vivas-Mejia PE et al. Sustained small interfering RNA delivery by mesoporous silicon particles. Cancer Res. 70(9), 3687-3696 (2010).
18. Owens DE, Peppas NA. Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int. J. Pharm. 307(1), 93-102 (2006).
19. Awasthi VD, Garcia D, Goins BA, Phillips WT. Circulation and biodistribution profiles of long-circulating PEG-liposomes of various sizes in rabbits. Int. J. Pharm. 253(1-2), 121-132 (2003).
20. Muthu MS, Kulkarni SA, Xiong JQ, Feng SS. Vitamin E TPGS coated liposomes enhanced cellular uptake and cytotoxicity of docetaxel in brain cancer cells. Int. J. Pharm. 421(2), 332-340 (2011).
21. Vasir JK, Labhasetwar V. Biodegradable nanoparticles for cytosolic delivery of therapeutics. Adv. Drug Delivery Rev. 59(8), 718-728 (2007).
22. Nori A, Kopecek J. Intracellular targeting of polymer-bound drugs for cancer chemotherapy. Adv. Drug Delivery Rev. 57(4), 609-636 (2005).
23. Win KY, Feng SS. Effects of particle size and surface coating on cellular uptake of polymeric nanoparticles for oral delivery of anticancer drugs. Biomaterials 26(15), 2713-2722 (2005).
24. Jiang W, Kim BYS, Rutka JT, Chan WCW. Nanoparticle-mediated cellular response is size-dependent. Nat. Nanotechnol. 3(3), 145-150 (2008).
25. Borchard G, Audus KL, Shi FL, Kreuter J. Uptake of surfactant-coated poly(methyl methacrylate)-nanoparticles by bovine brain microvessel endothelial-cell monolayers. Int. J. Pharm. 110(1), 29-35 (1994).
26. Koziara JM, Lockman PR, Allen DD, Mumper RJ. Paclitaxel nanoparticles for the potential treatment of brain tumors. J. Control. Release 99(2), 259-269 (2004).
27. Perry J, Laperriere N, Zuraw L, Chambers A, Spithoff K, Cairncross JG. Adjuvant chemotherapy for adults with malignant glioma: a systematic review. Can. J. Neurol. Sci. 34(4), 402-410 (2007).
28. Adamson C, Kanu OO, Mehta AI et al. Glioblastoma multiforme: a review of where we have been and where we are going. Expert Opin. Inv. Drug 18(8), 1061-1083 (2009).
29. Blanchette M, Fortin D. Blood-brain barrier disruption in the treatment of brain tumors. Methods Mol. Biol. 686, 447-463 (2011).
30. Gaillard PJ, Visser CC, Appeldoorn CCM, Rip J. Enhanced brain drug delivery: safely crossing the blood-brain barrier. Drug Discov. Today Technol. 9(2), e155-e160 (2012).
31. Tate MC, Aghi MK. Biology of angiogenesis and invasion in glioma. Neurotherapeutics 6(3), 447-457 (2009).
32. Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer-chemotherapy - mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 46(12), 6387-6392 (1986).
33. Perrault SD, Walkey C, Jennings T, Fischer HC, Chan WCW. Mediating tumor targeting efficiency of nanoparticles through design. Nano Lett. 9(5), 1909-1915 (2009).
34. Donelli MG, Zucchetti M, Dincalci M. Do anticancer agents reach the tumor target in the human brain. Cancer Chemother. Pharmacol. 30(4), 251-260 (1992).
35. Chertok B, Moffat BA, David AE et al. Iron oxide nanoparticles as a drug delivery vehicle for MRI monitored magnetic targeting of brain tumors. Biomaterials 29(4), 487-496 (2008).
36. Sarin H, Kanevsky AS, Wu HT et al. Physiologic upper limit of pore size in the blood-tumor barrier of malignant solid tumors. J. Transl Med. 7, 51 (2009).
37. Muldoon LL, Soussain C, Jahnke K et al. Chemotherapy delivery issues in central nervous system malignancy: a reality check. J. Clin. Oncol. 25(16), 2295-2305 (2007).
38. Groothuis DR. The blood-brain and blood-tumor barriers: A review of strategies for increasing drug delivery. Neuro. Oncol. 2(1), 45-59 (2000).
39. Nossek E, Ram Z, Bokstein F, Blumenthal D. Antiangiogenesis in recurrent glioblastoma: proof of principle. Neurol. Int. 1(1), e21 (2009).
40. Fukumura D, Jain RK. Tumor microenvironment abnormalities: causes, consequences, and strategies to normalize. J. Cell. Biochem. 101(4), 937-949 (2007).
41. Miladi I, Le Duc G, Kryza D et al. Biodistribution of ultra small gadolinium-based nanoparticles as theranostic agent: application to brain tumors. J. Biomater. Appl. doi:10.1177/0885328212454315 (2012) (Epub ahead of print).
42. Joshi S, Ergin A, Wang M et al. Inconsistent blood-brain barrier disruption by intraarterial mannitol in rabbits: implications for chemotherapy. J. Neuro. Oncol. 104(1), 11-19 (2011).
43. Xin HL, Jiang XY, Gu JJ et al. Angiopep-conjugated poly(ethylene glycol)-co-poly(epsilon-caprolactone) nanoparticles as dual-targeting drug delivery system for brain glioma. Biomaterials 32(18), 4293-4305 (2011).
44. Kratzer I, Wernig K, Panzenboeck U et al. Apolipoprotein A-I coating of protamine-oligonucleotide nanoparticles increases particle uptake and transcytosis in an in vitro model of the blood-brain barrier. J. Control. Release 117(3), 301-311 (2007).
45. Zensi A, Begley D, Pontikis C et al. Albumin nanoparticles targeted with Apo E enter the CNS by transcytosis and are delivered to neurones. J. Control. Release 137(1), 78-86 (2009).
46. Kreuter J, Alyautdin RN, Kharkevich DA, Ivanov AA. Passage of peptides through the blood-brain barrier with colloidal polymer particles (nanoparticles). Brain Res. 674(1), 171-174 (1995).
47. Wang CX, Huang LS, Hou LB et al. Antitumor effects of polysorbate-80 coated gemcitabine polybutylcyanoacrylate nanoparticles in vitro and its pharmacodynamics in vivo on C6 glioma cells of a brain tumor model. Brain Res. 1261, 91-99 (2009).
48. Gelperina S, Maksimenko O, Khalansky A et al. Drug delivery to the brain using surfactant-coated poly(lactide-co-glycolide) nanoparticles: influence of the formulation parameters. Eur. J. Pharm. Biopharm. 74(2), 157-163 (2010).
49. Chen YC, Hsieh WY, Lee WF, Zeng DT. Effects of surface modification of PLGA-PEG-PLGA nanoparticles on loperamide delivery efficiency across the blood-brain barrier. J. Biomater. Appl. 27(7), 909-922 (2011).
50. De Mendoza AEH, Preart V, Mollinedo F, Blanco-Prieto MJ. In vitro and in vivo efficacy of edelfosine-loaded lipid nanoparticles against glioma. J. Control. Release 156(3), 421-426 (2011).
51. Xie Y, Ye LY, Zhang XB et al. Transport of nerve growth factor encapsulated into liposomes across the blood-brain barrier: in vitro and in vivo studies. J. Control. Release 105(1-2), 106-119 (2005).
52. Lasa-Saracibar B, De Mendoza AEH, Guada M, Dios-Vieitez C, Blanco-Prieto MJ. Lipid nanoparticles for cancer therapy: state of the art and future prospects. Expert Opin. Drug Del. 9(10), 1245-1261 (2012).
53. Conner SD, Schmid SL. Regulated portals of entry into the cell. Nature 422(6927), 37-44 (2003).
54. Lu W, Tan YZ, Hu KL, Jiang XG. Cationic albumin conjugated pegylated nanoparticle with its transcytosis ability and little toxicity against blood-brain barrier. Int. J. Pharm. 295(1-2), 247-260 (2005).
55. Liu L, Guo K, Lu J et al. Biologically active core/shell nanoparticles self-assembled from cholesterol-terminated PEG-TAT for drug delivery across the blood-brain barrier. Biomaterials 29(10), 1509-1517 (2008).
56. Qin Y, Chen HL, Yuan WM et al. Liposome formulated with TAT-modified cholesterol for enhancing the brain delivery. Int. J. Pharm. 419(1-2), 85-95 (2011).
57. Liu Y, Huang RQ, Han L et al. Brain-targeting gene delivery and cellular internalization mechanisms for modified rabies virus glycoprotein RVG29 nanoparticles. Biomaterials 30(25), 4195-4202 (2009).
58. Van Rooy I, Mastrobattista E, Storm G, Hennink WE, Schiffelers RM. Comparison of five different targeting ligands to enhance accumulation of liposomes into the brain. J. Control. Release 150(1), 30-36 (2011).
59. Laron Z. Insulin and the brain. Arch. Physiol. Biochem. 115(2), 112-116 (2009).
60. Boado RJ, Zhang YF, Zhang Y, Pardridge WM. Humanization of anti-human insulin receptor antibody for drug targeting across the human blood-brain barrier. Biotechnol. Bioeng. 96(2), 381-391 (2007).
61. Ulbrich K, Knobloch T, Kreuter J. Targeting the insulin receptor: nanoparticles for drug delivery across the blood-brain barrier (BBB). J. Drug Target. 19(2), 125-132 (2011).
62. Ulbrich K, Hekmatara T, Herbert E, Kreuter J. Transferrin- and transferrin-receptor-antibody-modified nanoparticles enable drug delivery across the blood-brain barrier (BBB). Eur. J. Pharm. Biopharm. 71(2), 251-256 (2009).
63. Daniels TR, Delgado T, Rodriguez JA, Helguera G, Penichet ML. The transferrin receptor part I: biology and targeting with cytotoxic antibodies for the treatment of cancer. Clin. Immunol. 121(2), 144-158 (2006).
64. De Boer AG, Van Der Sandt ICJ, Gaillard PJ. The role of drug transporters at the blood- brain barrier. Annu. Rev. Pharmacol. Toxicol. 43, 629-656 (2003).
65. Gan CW, Feng SS. Transferrin-conjugated nanoparticles of poly(lactide)-d-alpha-tocopheryl polyethylene glycol succinate diblock copolymer for targeted drug delivery across the blood-brain barrier. Biomaterials 31(30), 7748-7757 (2010).
66. Sahoo SK, Labhasetwar V. Enhanced antiproliferative activity of transferrin-conjugated paclitaxel-loaded nanoparticles is mediated via sustained intracellular drug retention. Mol. Pharm. 2(5), 373-383 (2005).
67. Lu YJ, Sega E, Leamon CP, Low PS. Folate receptor-targeted immunotherapy of cancer: mechanism and therapeutic potential. Adv. Drug Delivery Rev. 56(8), 1161-1176 (2004).
68. Lefranc F, Brotchi J, Kiss R. Possible future issues in the treatment of glioblastomas: special emphasis on cell migration and the resistance of migrating glioblastoma cells to apoptosis. J. Clin. Oncol. 23(10), 2411-2422 (2005).
69. Mitchell P, Ellison DW, Mendelow AD. Surgery for malignant gliomas: mechanistic reasoning and slippery statistics. Lancet Neurol. 4(7), 413-422 (2005).
70. Sanai N, Berger MS. Glioma extent of resection and its impact on patient outcome. Neurosurgery 62(4), 753-764 (2008).
71. Kongkham P, Rutka JT, Piepmeier JM, Kaye AH, Black PM, Barker FG. Glioma extent of resection and its impact on patient outcome - comments. Neurosurgery 62(4), 764-766 (2008).
72. Giese A, Bjerkvig R, Berens ME, Westphal M. Cost of migration: invasion of malignant gliomas and implications for treatment. J. Clin. Oncol. 21(8), 1624-1636 (2003).
73. Kroin JS, Penn RD. Intracerebral chemotherapy: chronic microinfusion of cisplatin. Neurosurgery 10(3), 349-354 (1982).
74. Thorne RG, Nicholson C. In vivo diffusion analysis with quantum dots and dextrans predicts the width of brain extracellular space. Proc. Natl Acad. Sci. USA 103(14), 5567-5572 (2006).
75. Lu W, Wan J, Zhang Q, She Z, Jiang X. Aclarubicin-loaded cationic albumin-conjugated pegylated nanoparticle for glioma chemotherapy in rats. Int. J. Cancer 120(2), 420-431 (2007).
76. Nance EA, Woodworth GF, Sailor KA et al. A dense poly(ethylene glycol) coating Improves penetration of large polymeric nanoparticles within brain tissue. Sci. Transl Med. 4(149), 149ra119 (2012).
77. Fleming AB, Saltzman WM. Pharmacokinetics of the carmustine implant. Clin. Pharmacokinet. 41(6), 403-419 (2002).
78. Bobo RH, Laske DW, Akbasak A, Morrison PF, Dedrick RL, Oldfield EH. Convection-enhanced delivery of macromolecules in the brain. Proc. Natl Acad. Sci. USA 91(6), 2076-2080 (1994).
79. Sawyer AJ, Saucier-Sawyer JK, Booth CJ et al. Convection-enhanced delivery of camptothecin-loaded polymer nanoparticles for treatment of intracranial tumors. Drug Deliv. Transl Res. 1(1), 34-42 (2011).
80. Krauze MT, Noble CO, Kawaguchi T et al. Convection-enhanced delivery of nanoliposomal CPT-11 (irinotecan) and PEGylated liposomal doxorubicin (Doxil) in rodent intracranial brain tumor xenografts. Neuro. Oncol. 9(4), 393-403 (2007).
81. Saito R, Bringas JR, Mcknight TR et al. Distribution of liposomes into brain and rat brain tumor models by convection-enhanced delivery monitored with magnetic resonance imaging. Cancer Res. 64(7), 2572-2579 (2004).
82. Perlstein B, Ram Z, Daniels D et al. Convection-enhanced delivery of maghemite nanoparticles: increased efficacy and MRI monitoring. Neuro. Oncol. 10(2), 153-161 (2008).
83. Wu G, Barth RF, Yang WL, Kawabata S, Zhang LW, Green-Church K. Targeted delivery of methotrexate to epidermal growth factor receptor-positive brain tumors by means of cetuximab (IMC-C225) dendrimer bioconjugates. Mol. Cancer Ther. 5(1), 52-59 (2006).
84. Hadaczek P, Kohutnicka M, Krauze MT et al. Convection-enhanced delivery of adeno-associated virus Type 2 (AAV2) into the striatum and transport of AAV2 within monkey brain. Hum. Gene Ther. 17(3), 291-302 (2006).
85. Neeves KB, Sawyer AJ, Foley CP, Saltzman WM, Olbricht WL. Dilation and degradation of the brain extracellular matrix enhances penetration of infused polymer nanoparticles. Brain Res. 1180, 121-132 (2007).
86. Lidar Z, Mardor Y, Jonas T et al. Convection-enhanced delivery of paclitaxel for the treatment of recurrent malignant glioma: a Phase I/II clinical study. J. Neurosurg. 100(3), 472-479 (2004).
87. Lyons SA, O'Neal J, Sontheimer H. Chlorotoxin, a scorpion-derived peptide, specifically binds to gliomas and tumors of neuroectodermal origin. Glia 39(2), 162-173 (2002).
88. Veiseh O, Sun C, Fang C et al. Specific targeting of brain tumors with an optical/magnetic resonance imaging nanoprobe across the blood-brain barrier. Cancer Res. 69(15), 6200-6207 (2009).
89. Nam T, Park S, Lee SY et al. Tumor targeting chitosan nanoparticles for dual-modality optical/MR cancer imaging. Bioconjug. Chem. 21(4), 578-582 (2010).
90. Madhankumar AB, Slagle-Webb B, Mintz A, Sheehan JM, Connor Jr. Interleukin-13 receptor-targeted nanovesicles are a potential therapy for glioblastoma multiforme. Mol. Cancer Ther. 5(12), 3162-3169 (2006).
91. Simberg D, Duza T, Park JH et al. Biomimetic amplification of nanoparticle homing to tumors. Proc. Natl Acad. Sci. USA 104(3), 932-936 (2007).
92. Duan CX, Zhang DR, Wang FH et al. Chitosan-g-poly(N-isopropylacrylamide) based nanogels for tumor extracellular targeting. Int. J. Pharm. 409(1-2), 252-259 (2011).
93. Estrela JM, Ortega A, Obrador E. Glutathione in cancer biology and therapy. Crit. Rev. Clin. Lab. Sci. 43(2), 143-181 (2006).
94. Van Tellingen O, Brandsma D, Boogerd W et al. Gsh-conjugation improves efficacy of doxil against intracranial xenografts. Neuro. Oncol. 12, 34-34 (2010).
95. Aboody KS, Brown A, Rainov NG et al. Neural stem cells display extensive tropism for pathology in adult brain: evidence from intracranial gliomas. Proc. Natl Acad. Sci. USA 97(23), 12846-12851 (2000).
96. Nakamizo A, Marini F, Amano T et al. Human bone marrow-derived mesenchymal stem cells in the treatment of gliomas. Cancer Res. 65(8), 3307-3318 (2005).
97. Uchibori R, Okada T, Ito T et al. Retroviral vector-producing mesenchymal stem cells for targeted suicide cancer gene therapy. J. Gene Med. 11(5), 373-381 (2009).
98. Matuskova M, Hlubinova K, Pastorakova A et al. HSV-tk expressing mesenchymal stem cells exert bystander effect on human glioblastoma cells. Cancer Lett. 290(1), 58-67 (2010).
99. Sonabend AM, Ulasov IV, Tyler MA, Rivera AA, Mathis JM, Lesniak MS. Mesenchymal stem cells effectively deliver an oncolytic adenovirus to intracranial glioma. Stem Cells 26(3), 831-841 (2008).
100. Roger M, Clavreul A, Venier-Julienne MC et al. Mesenchymal stem cells as cellular vehicles for delivery of nanoparticles to brain tumors. Biomaterials 31(32), 8393-8401 (2010).
101. Wu X, Hu J, Zhou LF et al. In vivo tracking of superparamagnetic iron oxide nanoparticle-labeled mesenchymal stem cell tropism to malignant gliomas using magnetic resonance imaging. J. Neurosurg. 108(2), 320-329 (2008).
102. Huang X, Zhang F, Wang H et al. Mesenchymal stem cell-based cell engineering with multifunctional mesoporous silica nanoparticles for tumor delivery. Biomaterials 34(7), 1772-1780 (2013).
103. McGirt MJ, Than KD, Weingart JD et al. Gliadel (BCNU) wafer plus concomitant temozolomide therapy after primary resection of glioblastoma multiforme. J. Neurosurg. 110(3), 583-588 (2009).
104. Steiniger SCJ, Kreuter J, Khalansky AS et al. Chemotherapy of glioblastoma in rats using doxorubicin-loaded nanoparticles. Int. J. Cancer 109(5), 759-767 (2004).
105. Immonen A, Vapalahti M, Tyynela K et al. AdvHSV-tk gene therapy with intravenous ganciclovir improves survival in human malignant glioma: a randomised, controlled study. Mol. Ther. 10(5), 967-972 (2004).
106. Sandmair AM, Loimas S, Puranen P et al. Thymidine kinase gene therapy for human malignant glioma, using replication-deficient retroviruses or adenoviruses. Hum. Gene Ther. 11(16), 2197-2205 (2000).
107. Moolten FL. Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes - paradigm for a prospective cancer control strategy. Cancer Res. 46(10), 5276-5281 (1986).
108. Vecil GG, Lang FF. Clinical trials of adenoviruses in brain tumors: a review of Ad-p53 and oncolytic adenoviruses. J. Neuro. Oncol. 65(3), 237-246 (2003).
109. Chiocca EA, Abbed KM, Tatter S et al. A Phase I open-label, dose-escalation, multi-institutional trial of injection with an E1B-attenuated adenovirus, ONYX-015, into the peritumoral region of recurrent malignant gliomas, in the adjuvant setting. Mol. Ther. 10(5), 958-966 (2004).
110. Tai CK, Wang WJ, Chen TC, Kasahara N. Single-shot, multicycle suicide gene therapy by replication-competent retrovirus vectors achieves long-term survival benefit in experimental glioma. Mol. Ther. 12(5), 842-851 (2005).
111. Bogler O, Huang HJS, Kleihues P, Cavenee WK. The p53 gene and its role in human Brain-tumors. Glia 15(3), 308-327 (1995).
112. Tolcher AW, Hao D, De Bono J et al. Phase 1, pharmacokinetic, and pharmacodynamic study of intravenously administered Ad5CMV-p53, an adenoviral vector containing the wild-type p53 gene, in patients with advanced cancer. J. Clin. Oncol. 24(13), 2052-2058 (2006).
113. Lang FF, Bruner JM, Fuller GN et al. Phase I trial of adenovirus-mediated p53 gene therapy for recurrent glioma: biological and clinical results. J. Clin. Oncol. 21(13), 2508-2518 (2003).
114. Prados MD, Mcdermott M, Chang SM et al. Treatment of progressive or recurrent glioblastoma multiforme in adults with herpes simplex virus thymidine kinase gene vector-producer cells followed by intravenous ganciclovir administration: a Phase I/II multi-institutional trial. J. Neuro. Oncol. 65(3), 269-278 (2003).
115. Pulkkanen KJ, Yla-Herttuala S. Gene therapy for malignant glioma: current clinical status. Mol. Ther. 12(4), 585-598 (2005).
116. Putnam D. Polymers for gene delivery across length scales. Nat. Mater. 5(6), 439-451 (2006).
117. Voges J, Reszka R, Gossmann A et al. Imaging-guided convection-enhanced delivery and gene therapy of glioblastoma. Ann. Neurol. 54(4), 479-487 (2003).
118. Yoshida J, Mizuno M, Fujii M et al. Human gene therapy for malignant gliomas (glioblastoma multiforme and anaplastic astrocytoma) by in vivo transduction with human interferon beta gene using cationic liposomes. Hum. Gene Ther. 15(1), 77-86 (2004).
119. Hawkins CJ. Trail and malignant glioma. Vitam. Horm. 67, 427-452 (2004).
120. Lu W, Sun Q, Wan J, She ZJ, Jiang XG. Cationic albumin-conjugated pegylated nanoparticles allow gene delivery into brain tumors via intravenous administration. Cancer Res. 66(24), 11878-11887 (2006).
121. Van Houdt WJ, Haviv YS, Lu BG et al. The human survivin promoter: a novel transcriptional targeting strategy for treatment of glioma. J. Neurosurg. 104(4), 583-592 (2006).
122. Su ZZ, Sarkar D, Emdad L et al. Targeting gene expression selectively in cancer cells by using the progression-elevated gene-3 promoter. Proc. Natl Acad. Sci. USA 102(4), 1059-1064 (2005).
123. Cardoso ALC, Simoes S, De Almeida LP et al. SiRNA detivery by a transferrin-associated lipid-based vector: a non-viral strategy to mediate gene silencing. J. Gene Med. 9(3), 170-183 (2007).
124. Tzeng SY, Green JJ. Subtle changes to polymer structure and degradation mechanism enable highly effective nanoparticles for siRNA and DNA delivery to human brain cancer. Adv. Healthcare Mater. 2(3), 468-480 (2012).
125. Caruso G, Caffo M, Alafaci C et al. Could nanoparticle systems have a role in the treatment of cerebral gliomas? Nanomedicine 7(6), 744-752 (2011).
126. Furnari FB, Fenton T, Bachoo RM et al. Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev. 21(21), 2683-2710 (2007).
127. Kang CS, Zhang ZY, Jia ZF et al. Suppression of EGFR expression by antisense or small interference RNA inhibits U251 glioma cell growth in vitro and in vivo. Cancer Gene Ther. 13(5), 530-538 (2006).
128. Jordan A, Scholz R, Maier-Hauff K et al. The effect of thermotherapy using magnetic nanoparticles on rat malignant glioma. J. Neuro. Oncol. 78(1), 7-14 (2006).
129. Bachgansmo T. Ferrimagnetic susceptibility contrast agents. Acta Radiol. 34(387), 1-30 (1993).
130. Xie H, Zhu YH, Jiang WL et al. Lactoferrin-conjugated superparamagnetic iron oxide nanoparticles as a specific MRI contrast agent for detection of brain glioma in vivo. Biomaterials 32(2), 495-502 (2011).
131. Neuwelt EA, Varallyay P, Bago AG, Muldoon LL, Nesbit G, Nixon R. Imaging of iron oxide nanoparticles by MR and light microscopy in patients with malignant brain tumours. Neuropathol. Appl. Neurobiol. 30(5), 456-471 (2004).
132. Soenen SJH, Himmelreich U, Nuytten N, De Cuyper M. Cytotoxic effects of iron oxide nanoparticles and implications for safety in cell labelling. Biomaterials 32(1), 195-205 (2011).
133. Huang HC, Barua S, Sharma G, Dey SK, Rege K. Inorganic nanoparticles for cancer imaging and therapy. J. Control. Release 155(3), 344-357 (2011).
134. Kang MK, Kang SK. Tumorigenesis of chemotherapeutic drug-resistant cancer stem-like cells in brain glioma. Stem Cells Dev. 16(5), 837-847 (2007).
135. Clarke MF, Dick JE, Dirks PB et al. Cancer stem cells - perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res. 66(19), 9339-9344 (2006).
136. Silber J, Lim DA, Petritsch C et al. miR-124 and miR-137 inhibit proliferation of glioblastoma multiforme cells and induce differentiation of brain tumor stem cells. BMC Med. 6, 14 (2008).
137. Gangemi RMR, Griffero F, Marubbi D et al. SOX2 silencing in glioblastoma tumor-initiating cells causes stop of proliferation and loss of tumorigenicity. Stem Cells 27(1), 40-48 (2009).
138. Costantino L, Boraschi D. Is there a clinical future for polymeric nanoparticles as brain-targeting drug delivery agents? Drug Discov. Today 17(7-8), 367-378 (2012).
139. Stern ST, Hall JB, Yu LL et al. Translational considerations for cancer nanomedicine. J. Control. Release 146(2), 164-174 (2010).